TSE:BLU - BELLUS Health Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$1.50 -0.03 (-1.96 %)
(As of 03/26/2019 08:00 AM ET)
Previous CloseC$1.53
Today's RangeC$1.48 - C$1.53
52-Week RangeC$0.46 - C$1.69
Volume143,406 shs
Average Volume138,930 shs
Market CapitalizationC$235.56 million
P/E Ratio-20.00
Dividend YieldN/A
BetaN/A
BELLUS Health Inc., a biopharmaceutical company, engages in developing novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various other partnered clinical-stage drug development programs, including KIACTA, a novel drug candidate for the treatment of patients suffering from active pulmonary sarcoidosis; AMO-01 for Fragile X Syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. was founded in 1993 and is based in Laval, Canada.

Receive BLU News and Ratings via Email

Sign-up to receive the latest news and ratings for BLU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-450-6804500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$35,000.00
Cash FlowC$0.30 per share
Book ValueC$0.32 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$235.56 million
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable

BELLUS Health (TSE:BLU) Frequently Asked Questions

What is BELLUS Health's stock symbol?

BELLUS Health trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BLU."

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc (TSE:BLU) announced its quarterly earnings results on Thursday, February, 21st. The company reported ($0.02) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.02). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. View BELLUS Health's Earnings History.

When is BELLUS Health's next earnings date?

BELLUS Health is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for BELLUS Health.

What is the consensus analysts' recommendation for BELLUS Health?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BELLUS Health.

Has BELLUS Health been receiving favorable news coverage?

News coverage about BLU stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. BELLUS Health earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.

Who are some of BELLUS Health's key competitors?

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Extendicare (EXE), Suncor Energy (SU), XCel Brands (XELB), Athabasca Oil (ATH), Canadian Imperial Bank of Commerce (CM), Hydro One (H), Kimberly Clark (KMB), Inpixon (INPX), New Residential Investment (NRZ) and AT&T (T).

Who are BELLUS Health's key executives?

BELLUS Health's management team includes the folowing people:
  • Mr. Roberto Bellini, Pres, CEO & Director (Age 39)
  • Mr. François Desjardins C.A., CPA, CPA, CA, VP of Fin. (Age 56)
  • Dr. Denis Garceau, Sr. VP of Drug Devel. (Age 62)
  • Mr. Tony Matzouranis, VP of Bus. Devel. (Age 46)
  • Mr. Sébastien Roy, Corp. Sec. (Age 43)

How do I buy shares of BELLUS Health?

Shares of BLU and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is BELLUS Health's stock price today?

One share of BLU stock can currently be purchased for approximately C$1.50.

How big of a company is BELLUS Health?

BELLUS Health has a market capitalization of C$235.56 million and generates C$35,000.00 in revenue each year.

What is BELLUS Health's official website?

The official website for BELLUS Health is http://www.bellushealth.com.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada. The company can be reached via phone at +1-450-6804500.


MarketBeat Community Rating for BELLUS Health (TSE BLU)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  176
MarketBeat's community ratings are surveys of what our community members think about BELLUS Health and other stocks. Vote "Outperform" if you believe BLU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel